Every 10-Q that CeriBell, Inc. (CBLL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CBLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBLL filings page.
Ceribell, Inc. reported strong top-line growth but continued losses for the quarter and six months ended June 30, 2026. Total revenue rose to $28.1 million for the quarter and $54.6 million year-to-date, up 33% and 31% from 2025, driven by higher sales of disposable EEG Wearables and subscription fees as adoption expanded to more than 700 hospitals.
Gross margin improved to 92% in the quarter and 90% year-to-date, helped by scale and a $1.6 million IEEPA tariff refund. Operating expenses grew 36% year-to-date to $89.8 million, mainly from increased headcount, commercialization, and IP-related legal costs, leading to a net loss of $19.3 million for the quarter and $39.0 million year-to-date. The company held $129.3 million in cash, cash equivalents, and marketable securities and believes this will fund operations for at least 12 months. Subsequent to quarter-end, Ceribell refinanced its term loan with a new credit facility that includes a $30 million term loan commitment and a revolving line initially sized at $20 million, of which $20 million was drawn to repay the prior facility.
CeriBell, Inc. reported strong top-line growth but wider losses for the quarter ended March 31, 2026. Revenue rose 29% year over year to $26.5 million, driven evenly by product sales of Wearables at $20.2 million and subscription revenue of $6.3 million. Gross margin remained high at 87%, reflecting the scalable nature of its model.
Operating expenses increased 36% to $43.9 million, mainly from higher headcount across functions and significant legal spending tied to an intellectual property enforcement matter, leading to a net loss of $19.7 million versus $12.8 million a year earlier, or ($0.52) per share. EBITDA was a loss of $20.5 million, and Adjusted EBITDA, which excludes stock-based compensation and specified IP litigation costs, was a loss of $11.2 million.
CeriBell ended the quarter with $141.2 million in cash, cash equivalents, and marketable securities and $20.0 million of term debt outstanding. Management believes this liquidity, together with expected cash from customers, can fund planned operations and capital needs for at least the next 12 months.
CeriBell (CBLL) reported Q3 2025 results with total revenue of $22.589 million, up from $17.195 million a year ago, driven by product revenue of $17.020 million and subscription revenue of $5.569 million. Gross profit was $19.942 million.
Operating expenses rose to $34.589 million, leading to a net loss of $13.465 million (basic and diluted loss per share $0.37). For the nine months, revenue reached $64.279 million with a net loss of $39.885 million.
Liquidity remained strong with $168.5 million in cash, cash equivalents, and marketable securities as of September 30, 2025 ($23.739 million cash and $144.803 million marketable securities). Year‑to‑date operating cash outflow was $30.034 million. Notes payable carried value was $19.745 million. The company cites adoption in 600+ active accounts and use in 200,000+ patients as of the quarter end.